Jakeman, BernadetteBernadetteJakemanScherrer, Alexandra UAlexandra UScherrerDarling, Katharine E AKatharine E ADarlingDamas, JoseJoseDamasBieler-Aeschlimann, MelanieMelanieBieler-AeschlimannHasse, BarbaraBarbaraHasseSchlosser, LadinaLadinaSchlosserHachfeld, AnnaAnnaHachfeldGutbrod, KlemensKlemensGutbrodTarr, Philip EPhilip ETarrCalmy, AlexandraAlexandraCalmyAssal, FredericFredericAssalKunze, UrsulaUrsulaKunzeStoeckle, MarcelMarcelStoeckleSchmid, PatrickPatrickSchmidToller, GianinaGianinaTollerRossi, StefaniaStefaniaRossidi Benedetto, CarolineCarolinedi Benedettodu Pasquier, RenaudRenauddu PasquierCavassini, MatthiasMatthiasCavassiniMarzolini, CatiaCatiaMarzolini2024-10-112024-10-112022-09https://boris-portal.unibe.ch/handle/20.500.12422/87686Background We previously showed that anticholinergic (ACH) medications contribute to self-reported neurocognitive impairment (NCI) in elderly people with human immunodeficiency virus (PWH). The current cross-sectional study further evaluated the effect of ACH and sedative drugs on neurocognitive function in PWH who underwent comprehensive neuropsychological evaluation. Methods A medication review was performed in PWH enrolled in the prospective Neurocognitive Assessment in Metabolic and Aging Cohort within the Swiss HIV Cohort Study. Neurocognitive functions were analyzed in 5 domains (motor skills, speed of information, attention/working memory, executive functions, and verbal learning memory). The effect of ACH and sedative medications on neurocognitive functioning was evaluated using linear regression models for the continuous (mean z-score) outcome and multivariable logistic regression models for the binary (presence/absence) outcome. Results A total of 963 PWH (80% male, 92% Caucasian, 96% virologically suppressed, median age 52) were included. Fourteen percent of participants were prescribed ≥1 ACH medication and 9% were prescribed ≥1 sedative medication. Overall, 40% of participants had NCI. Sedative medication use was associated with impaired attention/verbal learning and ACH medication use with motor skills deficits both in the continuous (mean z-score difference -0.26 to -0.14, P < .001 and P = .06) and binary (odds ratio [OR], ≥1.67; P < .05) models. Their combined use was associated with deficits in overall neurocognitive functions in both models (mean z-score difference -0.12, P = .002 and OR = 1.54, P = .03). These associations were unchanged in a subgroup analysis of participants without depression (n = 824). Conclusions Anticholinergic and sedative medications contribute to NCI. Clinicians need to consider these drugs when assessing NCI in PWH.enHIV anticholinergic medication neuro-HIV neurocognitive impairment sedative medication600 - Technology::610 - Medicine & healtharticle10.48350/1732263614759810.1093/ofid/ofac457